-
14m 12sPart 1 | Session 2 Evolut in SAPIEN
-
16m 29sPart 1 | Session 3 Evolut in Evolut
-
17m 38sPart 1 | Session 4 SAPIEN in Evolut & Explant Data
-
4m 19sPart 1 | Session 5 Live Q&A Panel
-
1m 23sPart 2 | Session 1 Welcome and Introduction
-
14m 19sPart 2 | Session 2 Evolut in SAPIEN
-
11m 49sPart 2 | Session 3 Evolut in Evolut
-
16m 10sPart 2 | Session 4 TAVR Explant
-
10m 2sPart 2 | Session 5 Live Q&A Panel
The Future of TAVR: Redo TAV webinar series showcases the latest approaches to managing redo TAV procedures. Join the first in the series where Guilherme Attizzani (Cleveland, US), Cezar S. Staniloae (New York, US) Chad Rammohan (Mountain View & Redwood City, US) and Toby Rogers (Washington, US) feature step-by-step CT case planning and valve sizing, followed by an engaging case-based discussion of redo TAV scenarios, including how different TAVR valve combinations influenced planning and outcomes. Practical insights were shared on how experts approached these cases in real-world practice.
• Expert implanters shared cases addressing common procedural and clinical best practices and tips
• Terminology, redo TAV combination considerations and planning principles were reviewed
• Precision planning focused on the role of CT in redo TAV and procedural strategies
• Future TAVR principles were incorporated when considering index TAV and redo TAV
Key Learning Objectives
- Understand CT sizing, case planning and CT algorithm for Redo TAV with Evolut
- Address common procedural and clinical challenges using practical insights and solutions identified from real-world physician experience
- Apply case-based clinical decision-making to select appropriate treatment approaches across a range of redo TAV scenarios
- Evaluate TAVR and redo TAV treatment pathways within the context of patient's lifespan
Target Audience
- Interventional Cardiologists
- Structural Heart Intervention Specialist
- Cardiac Imaging Specialists
- Cardiothoracic surgeon
More from this programme
Part 1
The Future of TAVR: Redo TAV - Session I
Part 2
The Future of TAVR: Redo TAV - Session 2
Faculty Biographies
Guilherme Ferragut Attizzani
Interventional Cardiologist
Dr Guilherme Attizzani is an Interventional Cardiologist at University Hospitals in Cleveland, OH. He specializes in structural heart disease and complex coronary interventions, with extensive experience in transcatheter aortic valve replacement (TAVR) and Redo TAV procedures. Dr. Attizzani has contributed to numerous clinical trials and registries focused on advancing outcomes in structural heart interventions.
Cezar S. Staniloae
Interventional Cardiologist
Dr Cezar S. Staniloae is an Interventional Cardiologist at NYU Langone Health in New York, NY. With a distinguished career in structural and interventional cardiology, he has been at the forefront of transcatheter valve therapies. His clinical expertise includes complex TAVR cases, valve-in-valve procedures, and the management of high-risk surgical patients.
Chad Rammohan
Interventional Cardiologist
Dr Chad Rammohan is a distinguished interventional cardiologist with over two decades of experience in cardiovascular medicine, structural heart interventions, and clinical research. He currently serves as the Director of the Cardiac Catheterization Laboratory and Structural Heart Program at El Camino Hospital in Mountain View, California, and Sequoia Hospital in Redwood City.
Dr Rammohan completed his medical degree at Washington University School of Medicine in St. Louis, where he was inducted into Alpha Omega Alpha and received multiple academic honors. He earned his undergraduate degree in Bioengineering with a minor in Chemistry from the University of Illinois, graduating with high distinction.
His postgraduate training includes a residency in Internal Medicine at UCSF, where he was honored as both Junior and Senior Resident of the Year, followed by fellowships in General and Interventional Cardiology at Northwestern University, where he also served as Chief…
Toby Rogers
Interventional Cardiologist and Scientific Lead
Dr. Rogers in an interventional cardiologist and scientific lead for the MedStar Heart & Vascular Institute Structural Heart Disease program.